Tarim Mahmood* and Bhaskar Chakraborty
DOI: 10.37421/ 2576-3857.2022.7.002
Seeram Ramakrishna
A core of several tetraspanin proteins organizes other membrane proteins like growth factor receptors, integrins, and Human Leukocyte Antigen (HLA) antigens in these complexes. Albeit most tetraspanin proteins have been concentrated separately, tetraspanin proteins and their edifices can affect cell grip and motility, associations with stroma or influence announcing development factors, and for the greater part of them no ligand has been distinguished. Although they are found in all cell types, these proteins have primarily been studied functionally in lymphoid cells. Tetraspanins have been identified as metastasis suppressors in some tumors, but their significance is still unclear. Data are also available for these tumors. They are outlined, along with some of their implications for tumor biology and areas that require additional research. The biological properties of tumor cells, particularly those pertaining to tumor adhesion and dissemination, can be significantly affected by membrane proteins that are involved in cellular interactions with other cells or the stroma as well as signaling pathways. The tetraspanins, a brand-new class of membrane proteins, are beginning to gain importance in cell biology but have received very little attention in the context of cancer biology up until this point.
Wenbin Lin
Heterochromatin Protein 1α (HP1α) is a critical player in chromatin organization and gene regulation, and its dysregulation has been implicated in various cellular processes, including cell proliferation and cancer development. This review focuses on the role of HP1α as a characteristic of cell proliferation that is pertinent to clinical oncology. Extensive research has demonstrated that HP1α plays a dual role in regulating cell proliferation. On one hand, it functions as a transcriptional repressor, modulating the expression of genes involved in cell cycle control and DNA replication. On the other hand, HP1α has also been found to interact with numerous signaling pathways and transcription factors, thereby promoting cell proliferation under certain conditions. Aberrant expression and localization of HP1α have been observed in various types of cancer, including breast, prostate, lung, and colorectal cancer. Furthermore, studies have shown that altered HP1α expression is associated with poor prognosis and resistance to conventional therapies in cancer patients. Understanding the molecular mechanisms underlying HP1α's involvement in cell proliferation is of significant interest in clinical oncology. Targeting HP1α and its associated pathways may offer promising therapeutic opportunities for cancer treatment. In addition, HP1α expression levels and subcellular localization can potentially serve as diagnostic and prognostic biomarkers in clinical practice.
Cancer Biology
Overall Survival (OS) is regarded as the most trustworthy and preferred endpoint in oncology trials to evaluate drug treatment benefits. In order to speed up and streamline the development of clinical oncology drugs, it is critical to identify the dynamic effects and connections between the various variables collected from patients for a given drug and its indication. Due to temporal differences, drug-induced effects and causal relationships can be difficult to interpret. Parametric time-to-event models and population pharmacokinetic– pharmacodynamic modeling are increasingly being used to address this issue.
Lu Wang*
Tamil Selvan S*
Cancer is a life-threatening disease that claims the lives of 3.4 million people each year around the world. Smoking, being overweight or obese, eating processed meat, radiation, family history, stress, environmental variables, and chance are all factors that contribute to cancer. Surgical excision of solid tumors, radiation therapy, and chemotherapy are the first-line treatments for cancer. The fundamental clinical failure of chemotherapy in cancer treatment is systemic delivery of the free drug, because only a little amount of the drug reaches the tumor site. The majority of chemotherapy Active Pharmaceutical Ingredients (APIs) are extremely cytotoxic to both cancer and normal cells. As a result, focusing on the tumor vasculatures is critical for tumor treatment. Encapsulation of anti-cancer medications within the liposomal system provides secure platforms for the delivery of these drugs in this context.
Khalid Hadadi, Mouhcine Hommadi*, Elktaibi Abderrahim, Oukabli Mohammed and Hassan Sifat
Prostate cancer is among the most common cancers in males worldwide. Those diagnosed may undergo a variety of treatments ranging from radiation to surgery to chemotherapy and hormonal therapy. Although clinicians often encounter metastases in bones and lymph nodes, there are instances where the spread occurs to more unconventional sites. Here, we document a peculiar scenario involving a 76-year-old individual who had undergone prior treatment for prostate adenocarcinoma. This patient manifested symptomatic metastases specifically in the right testis and a lymph node, without evident widespread disease that might initially suggest a primary testicular tumor. This case report underscores the importance of contemplating the potential for metastatic disease in the differential diagnosis when assessing patients with a history of prostate cancer and a newly discovered mass. This consideration should persist until a whole evaluation of the tissue is conducted.
Journal of Oncology Medicine & Practice received 142 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 